News Release

Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC

SAN DIEGO--(BUSINESS WIRE)--Apr. 3, 2017--
Illumina,
Inc. (NASDAQ: ILMN) today announced it is contributing more than
8,000 associations of somatic genetic alterations—variants linked to
tumors—to the Clinical Interpretation of Variants in Cancer (CIViC)
resource, an openly accessible database hosted by Washington University
in St. Louis that can be used in precision medicine. Illumina’s donation
triples the number of associations in the CIViC database, making
Illumina the largest donor to this open access project.

“We are very excited and grateful to receive this substantial
contribution from Illumina. The open-access model of CIViC was
consciously chosen to allow for these kinds of submissions,” said Obi L.
Griffith, Assistant Professor of Medicine at Washington University
School of Medicine, St. Louis. “This genetic information represents a
very valuable data set that is now available to researchers worldwide.
CIViC's strategy is to break down information silos between academic and
industry researchers. This donation shows that such a strategy can work.”

The donation includes information linked to cancer therapies and cancer
subtyping to help clinical researchers identify relevant information
associated with tumor variants gathered from publications and drug
labels. The 8,000 associations cover more than 3,500 unique variants
extracted from close to 700 scientific publications. It includes 74
drugs associated with 100 cancer types that have been collected over 5
years by a team of scientists. The standards employed for variant
curation are similar to those recently published by the Association for
Molecular Pathology (AMP), American Society of Clinical Oncology (ASCO),
and College of American Pathologist (CAP).

The donated interpretations, with evidence linked directly to their
peer-reviewed source publications, will help clinical research
laboratories engage in precision oncology. These variant associations
are available within BaseSpace
Variant Interpreter (Beta), for use in aiding in interpreting the
significance of individuals’ genetic variants. Illumina recently made a
similar donation of 95,000 human genetic variants to ClinVar to assist
with rare disease diagnosis.

Consistent with draft guidance documents released by the FDA on July 6,
public genetic variant databases such as CIViC and ClinVar can play an
important role in establishing the clinical validity of assertions made
between variants detected by a next-generation sequencing-based test and
a disease or condition.

“This extensive data set will expand our shared genomic knowledge and
enable researchers to design personalized therapeutics which aids in
advancing genomics into healthcare,” said Sanjay Chikarmane, Senior Vice
President and General Manager at Illumina. “The donation to CIViC and
ClinVar represents our commitment to help researchers access and share
the secure health data information they need to transform healthcare.”

About Illumina

Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture and other emerging segments. To learn more, visit www.illumina.com and
follow @illumina.

About CIViC

The CIViC project is an ecosystem of curators, moderators and other
stakeholders that aims to facilitate a collaborative ecosystem of
research scientists, clinical scientists, and patient advocates
dedicated to creating an accurate and relevant database of clinical
interpretations of cancer variants. To learn more, visit https://civic.genome.wustl.edu.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are
not limited to, statements we make regarding the expected availability
dates for new products and services and FDA submission dates and
intentions for certain products and services. Important factors that
could cause actual results to differ materially from those in any
forward-looking statements include challenges inherent in developing,
manufacturing, and launching new products and services, and the other
factors that are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms 10-K and
10-Q, or in information disclosed in public conference calls, the date
and time of which are released beforehand. We do not intend to update
any forward-looking statements after the date of this release.